Landos Biopharma, Inc.
LABPDelisted May 23, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785345
Landos Biopharma, Inc. was delisted on May 23, 2024; its insiders filed their last Form 4 on May 23, 2024; 16 institutions reported holding it in 13F filings for Q1 2024, worth $34.9M in total; no superinvestor held it.
13F holders, Q3 2021
Institutional positions in Landos Biopharma, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 35
- +2 vs. Q2 2021
- Shares held
- 22.7M
- −39.0K (−0.2%) vs. Q2 2021
- Total value
- $331.1M
- +$69.6M (+26.6%) vs. Q2 2021
- New holders
- 5
- 10 more added
- Sold out
- 3
- 15 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LABP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 16 | $34.9M |
| Q4 2023 | 10 | $5.58M |
| Q3 2023 | 11 | $5.93M |
| Q2 2023 | 8 | $6.27M |
| Q1 2023 | 20 | $4.63M |
| Q4 2022 | 23 | $7.87M |
| Q3 2022 | 31 | $14.0M |
| Q2 2022 | 35 | $16.4M |
| Q1 2022 | 45 | $35.3M |
| Q4 2021 | 40 | $119.8M |
| Q3 2021 | 35 | $331.1M |
| Q2 2021 | 33 | $261.4M |
| Q1 2021 | 47 | $218.9M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Landos Biopharma, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cahill Financial Advisors Inc | 100 | $1.00K | 0.00% | +100 | New |
| Carroll Financial Associates, Inc. | 393 | $5.00K | 0.00% | +343+686.0% | Added |
| Legal & General Group Plc | 408 | $6.00K | 0.00% | −181−30.7% | Reduced |
| Ameritas Investment Partners, Inc. | 515 | $8.00K | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 548 | $8.00K | 0.00% | +241+78.5% | Added |
| Royal Bank of Canada | 619 | $9.00K | 0.00% | +176+39.7% | Added |
| Tower Research Capital LLC (TRC) | 652 | $10.0K | 0.00% | −778−54.4% | Reduced |
| Geneos Wealth Management Inc. | 1,100 | $16.0K | 0.00% | +1,000+1,000.0% | Added |
| Bank of America Corp | 1,486 | $22.0K | 0.00% | −9,737−86.8% | Reduced |
| Morgan Stanley | 1,743 | $26.0K | 0.00% | −5,169−74.8% | Reduced |
| California State Teachers Retirement System | 2,530 | $37.0K | 0.00% | −6,431−71.8% | Reduced |
| American International Group, Inc. | 2,563 | $37.0K | 0.00% | −1,058−29.2% | Reduced |
| Deutsche Bank AG | 2,693 | $39.0K | 0.00% | −1,156−30.0% | Reduced |
| New York State Common Retirement Fund | 2,756 | $40.0K | 0.00% | −4,600−62.5% | Reduced |
| Allworth Financial LP | 5,286 | $77.0K | 0.00% | +5,286 | New |
| Renaissance Technologies LLC | 10,900 | $159.0K | 0.00% | +10,900 | New |
| STRS Ohio | 11,400 | $166.0K | 0.00% | +9,900+660.0% | Added |
| Charles Schwab Investment Management Inc | 13,960 | $204.0K | 0.00% | +518+3.9% | Added |
| Bank of New York Mellon Corp | 14,953 | $218.0K | 0.00% | +924+6.6% | Added |
| Jacobs Levy Equity Management, Inc | 18,174 | $265.0K | 0.00% | +18,174 | New |
| Cambridge Investment Research Advisors, Inc. | 18,831 | $275.0K | 0.00% | +18,831 | New |
| Northern Trust Corp | 46,680 | $682.0K | 0.00% | −27,239−36.8% | Reduced |
| State Street Corp | 107,566 | $1.57M | 0.00% | +15,199+16.5% | Added |
| Geode Capital Management, LLC | 112,933 | $1.65M | 0.00% | −14,585−11.4% | Reduced |
| Ensign Peak Advisors, Inc | 125,000 | $1.82M | 0.00% | 00.0% | Unchanged |
| Botty Investors LLC | 128,750 | $1.88M | 0.56% | +5,969+4.9% | Added |
| Macquarie Group Ltd | 147,182 | $2.15M | 0.00% | 00.0% | Unchanged |
| Woodline Partners LP | 212,800 | $3.11M | 0.05% | −535−0.3% | Reduced |
| BlackRock Inc. | 233,616 | $3.41M | 0.00% | −60,427−20.6% | Reduced |
| OrbiMed Advisors LLC | 283,217 | $4.13M | 0.05% | −397,783−58.4% | Reduced |
| Vanguard Group Inc | 304,794 | $4.45M | 0.00% | −391−0.1% | Reduced |
| JPMorgan Chase & Co | 309,992 | $4.53M | 0.00% | −64,838−17.3% | Reduced |
| Logos Global Management LP | 1,405,000 | $20.5M | 1.48% | +505,894+56.3% | Added |
| RTW Investments, LP | 4,275,722 | $62.4M | 0.94% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 14,869,915 | $217.1M | 3.16% | 00.0% | Unchanged |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −17,793−100.0% | Sold out |
| Nuveen Asset Management, LLC | 0 | $0 | 0.00% | −10,219−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −9,526−100.0% | Sold out |